Miraculins, Fox Chase Cancer Center to validate colorectal cancer markers

By Lisa Kerner

Charlotte, N.C., June 13 - Miraculins Inc. said it is collaborating with Fox Chase Cancer Center in Philadelphia to further the development of Miraculins' colorectal cancer diagnostic project.

Under the collaboration, Miraculins will begin the validation phase of its research to develop a colorectal diagnostic test.

Fox Chase will provide biological samples donated by patients anonymously.

In a study to verify the colorectal biomarkers, Miraculins said it was able to correctly identify cancer positives and those without cancer with a sensitivity and specificity of greater than 80% and 80%, respectively.

With more than 150,000 new cases diagnosed annually, colorectal cancer is one of the most prevalent cancers in North America.

Current diagnostic methods for colorectal cancer are primarily image based, invasive and expensive, Miraculins said.

Fox Chase, the nation's first cancer hospital, conducts research, prevention, detection and treatment programs for cancer.

Located in Winnipeg, Man., Miraculins discovers, validates and develops biological markers for the diagnosis and treatment of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.